Exactly half of respondents to a GEN poll say their companies are working to gain provider acceptance and reimbursement for personalized medicine by pursuing standard-of-care status for their molecular diagnostics. Another third (33.3%) are concentrating their efforts on developing diagnostics for markets outside the U.S., while 16.7% said they are forming partnerships with the pharmaceutical industry. Steven Burrill, CEO of Burrill & Company, has likened gaining acceptance for personalized medicine diagnostics to hand-to-hand combat: “Investors were naïve at how substantial and perverse the resistance to adoption is.”

Previous articleValeant Proposes $314M Take Over of ISTA to Its Board of Directors
Next articleFirms Are Upping the Stakes on mAb Biosimilar Development